100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Summary BNF Drug Summaries - Nervous System £0.00

Summary

Summary BNF Drug Summaries - Nervous System

 101 views  15 purchases

A 17-page concise summary of the nervous system intended to facilitate preparation for the GPhC registration exam. These notes can also be used as a quick reference guide or a resource to refresh general clinical pharmacy knowledge, perfect for pre-registration pharmacists, medical students, and tr...

[Show more]

Preview 3 out of 17  pages

  • No
  • Chapter 4 - nervous system
  • June 8, 2021
  • 17
  • 2020/2021
  • Summary
book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:
All documents for this subject (239)
avatar-seller
humzaibrahim
Drug Summaries – Humza Ibrahim
2.1 Hypnotics & anxiolytics ................................ 7
Chapter 4 2.1.1 Hypnotics ............................................. 7
Nervous System 2.1.2 Anxiolytics ............................................ 7
2.2 Dependence and Withdrawal ...................... 7

TABLE OF CONTENTS 2.3 Barbiturates ................................................. 7
2.4 Benzodiazepines .......................................... 7
Table of Contents ......................................................... 1
2.4.1 Benzodiazepine Indications ................. 7
1 Epilepsy and other seizure disorders ............... 3
2.4.2 Types of benzodiazepines .................... 7
1.1 MHRA/CHM advice ...................................... 3
2.4.3 Side Effects - Overdose ........................ 7
1.2 Withdrawal................................................... 3
2.4.4 Paradoxical effects ............................... 7
1.3 Driving .......................................................... 3
2.4.5 Elderly .................................................. 7
1.4 Pregnancy..................................................... 4
3 Attention deficit hyperactivity disorder .......... 7
1.5 Breastfeeding ............................................... 4
3.1 Atomoxetine ................................................ 7
1.6 Antiepileptic hypersensitivity syndrome ..... 4
3.2 Dexsamfetamine & Lidexasamfetamine ...... 8
1.7 Types of Seizures .......................................... 4
4 Bipoalr disorder and mania ............................. 8
1.7.1 Focal
4.1 Lithium (high risk) ........................................ 8
(small part of the brain is affected) ..................... 4
4.1.1 Warning signs....................................... 8
1.7.2 Generalised
(most/all of the brain is affected) ........................ 4 4.1.2 Monitoring ........................................... 8
1.7.3 Status Epilepticus ................................. 4 4.1.3 Driving and skilled tasks ....................... 8
1.8 Carbamazepine (high risk) ........................... 5 4.1.4 Interactions .......................................... 8
1.8.1 Warning signs ....................................... 5 4.1.5 Cautions ............................................... 8
1.8.2 Monitoring ........................................... 5 4.1.6 Dose equivalence and conversion ....... 8
1.8.3 Hepatic ................................................. 5 4.1.7 Other points ......................................... 8
1.8.4 Pregnancy and breastfeeding .............. 5 5 Antidepressant drugs ....................................... 9
1.8.5 Drug interactions.................................. 5 5.1 St John's wort............................................... 9
1.9 Fosphenytoin................................................ 5 5.2 Hyponatraemia and
antidepressant therapy ........................................... 9
1.10 Gabapentin................................................... 5
5.3 Suicidal behaviour and antidepressant
1.11 Lamotragine ................................................. 5
therapy..................................................................... 9
1.11.1 Blood disorders .................................... 5
5.4 Serotonin syndrome .................................... 9
1.11.2 Skin reactions ....................................... 5
5.5 Monoamine-oxidase inhibitors .................... 9
1.12 Phenytoin (high risk) .................................... 6
5.6 Selective serotonin re-uptake inhibitors ..... 9
1.12.1 Dose equivalence and conversion ....... 6
5.6.1 Paroxetine and venlafaxine ............... 10
1.12.2 Warning signs ....................................... 6
5.7 Tricyclic and related antidepressants ........ 10
1.12.3 Drug interactions.................................. 6
5.8 Agomelatine ............................................... 10
1.13 Sodium Valproate......................................... 6
6 Psychoses and schizophrenia......................... 10
1.14 Topiramate ................................................... 6
6.1 doses of antipsychotic drugs above bnf
1.15 Vigabatrin ..................................................... 6 upper limit ............................................................. 10
1.16 Benzodiazepines .......................................... 6 6.2 Emergency treatment ................................ 11
2 Sleep Disorders ................................................ 6 6.3 Prescribing for the elderly ......................... 11

Chapter 4 – Pg 1
Compiled using the British National Formulary

, Drug Summaries – Humza Ibrahim
6.4 Anti-psychotic drugs .................................. 11 12 Antimigraine drugs ........................................ 15
6.4.1 Typical (fist-generation) ..................... 11 12.1 Ergotamine................................................. 15
6.4.2 Atypical (second-generation) ............. 11 13 Substance Dependence ................................. 16
6.5 Side effects ................................................. 11 13.1 Alcohol dependence .................................. 16
6.5.1 Extrapyramidal symptoms ................. 11 13.1.1 Acute alcohol withdrawal .................. 16
6.5.2 Hyperprolactinaemia ......................... 11 13.1.2 Drugs used in alcohol dependence .... 16
6.5.3 Sexual dysfunction ............................. 11 13.2 Nicotine dependence ................................. 16
6.5.4 Cardiovascular .................................... 11 13.2.1 Concomitant medication ................... 16
6.5.5 Hyperglycaemia, 13.2.2 Varenicline ......................................... 16
weight gain, and diabetes .................................. 11 13.3 Opioid dependence.................................... 16
6.5.6 Hypotension and interference with 13.3.1 Opioid substitution therapy ............... 16
temperature regulation ..................................... 11
13.3.2 Pregnancy and breastfeeding ............ 16
6.6 Monitoring ................................................. 11
13.3.3 Methadone ........................................ 17
6.7 Chlorpromazine.......................................... 12
13.3.4 QT-interval prolongation ................... 17
6.8 Pimozide ..................................................... 12
13.3.5 Side effects......................................... 17
6.9 Clozapine .................................................... 12
6.10 Olanzapine ................................................. 12
7 Parkinson’s disease ........................................ 12
7.1 Dopaminergic drugs ................................... 12
7.1.1 Bromocriptine,
Cabergoline, and Pergolide ................................ 13
7.1.2 Pramipexole ....................................... 13
8 Nausea and vertigo ........................................ 13
8.1 Pregnancy................................................... 13
8.2 Motion sickness ......................................... 13
8.3 Ménière's disease ...................................... 13
8.4 Domperidone ............................................. 13
8.5 Metoclopramide ........................................ 13
9 Non-opioid analgesics .................................... 14
9.1 Ibuprofen doses ......................................... 14
9.2 Paracetamol doses ..................................... 14
10 Opiates (high risk) ......................................... 14
10.1 Warning signs ............................................. 14
10.2 Dependence and tolerance ........................ 14
10.3 Monitoring ................................................. 15
10.4 Interactions ................................................ 15
10.5 Other points ............................................... 15
10.6 Codeine ...................................................... 15
10.7 Fentanyl...................................................... 15
11 Neuropathic pain ........................................... 15

Chapter 4 – Pg 2
Compiled using the British National Formulary

, Drug Summaries – Humza Ibrahim
Risk-based categories of antiepileptic drugs
Chapter 4
1. Patient should be maintained on a specific brand
Nervous System Phenytoin, carbamazepine, phenobarbital,
primidone
2. Supply of a specific brand based on clinical
1 EPILEPSY AND OTHER SEIZURE judgment
Valproate, lamotrigine, perampanel, retigabine,
DISORDERS rufinamide, clobazam, clonazepam,
oxcarbazepine, eslicarbazepine, zonisamide,
The main aim of treatment is to prevent the topiramate
occurrence of seizures by maintaining an effective 3. Unnecessary to supply a specific brand
dose of one or more antiepileptic drugs. Dosage Levetiracetam, lacosamide, tiagabine,
frequency should be kept as low as possible to gabapentin, pregabalin, ethosuximide, vigabatrin
encourage adherence, however large doses may
require frequent doses to avoid adverse effects Risk of suicidal thoughts and behaviour
associated with high plasma-drug concentration. All antiepileptic drugs are associated with a small
increased risk of suicidal thoughts and behaviour.
Monotherapy with first or second line antiepileptic Patients should seek medical advice if the develop
drug is preferred, as the concurrent use of multiple symptoms which may occur as early as one week after
drugs increases the risk of adverse effects and drug starting treatment.
interactions. When changing from one antiepileptic to
another, the first drug should be slowly withdrawn.
1.2 WITHDRAWAL
Avoid abrupt withdrawal. Reduction in dosage should
1.1 MHRA/CHM ADVICE be gradual and, in the case of barbiturates,
Switching between different manufacturers’ products withdrawal of the drug may take months. There is a
Loss of seizure control and/or worsening of side- significant risk of seizure recurrence on drug
effects may be associated with but not excluded to withdrawal. In patients receiving several antiepileptic
switching between products. drugs, only one drug should be withdrawn at a time.
The following guidance has been issued to help
minimise risk: 1.3 DRIVING
• Antiepileptic drugs have been divided into three Patients with epilepsy may drive a motor vehicle (but
risk-based categories to decide whether it is not a large goods or passenger carrying vehicle)
necessary to maintain continuity of supply of a provided that they have:
specific manufacturer’s product • Been seizure-free for one year or,
• If a patient is to be maintained on a specific • Established a 3-year period of asleep attacks
manufacturer’s product this should be without awake attacks
prescribed either by specifying a brand name,
or by using the generic drug name and name of Those affected by drowsiness should not drive or
the manufacturer operate machinery. DVLA recommends that patients
• This advice relates only to antiepileptic drug use should not to drive during medication changes or
for treatment of epilepsy; it does not apply to withdrawal of antiepileptic drugs, and for 6 months
their use in other indications (e.g. mood afterwards.
stabilisation, neuropathic pain);
• Please report on a Yellow Card any suspected
adverse reactions to antiepileptic drugs
• If a prescribed product is unavailable, it may be
necessary to dispense a product from a
different manufacturer to maintain continuity
of treatment of that antiepileptic drug



Chapter 4 – Pg 3
Compiled using the British National Formulary

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller humzaibrahim. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for £0.00. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77254 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy revision notes and other study material for 14 years now

Start selling
Free  15x  sold
  • (0)